Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22356644 | 0.77 | RXFP1 (0.43) | NPY5RNPC1RAB9ATNIKIDO1 | |
| SCHEMBL22356643 | 0.73 | NPY5R (0.41) | NPY5RNPC1RAB9ATNIK | |
| SCHEMBL3768295 | 0.70 | ADORA3 (0.58) | ADORA3NPC1IDO1 | |
| SCHEMBL2873998 | 0.69 | CCNA2 (0.54) | NPC1RAB9ATNIKALPL | |
| Hydrochloric Acid SCHEMBL11401357 | 0.69 | ADORA3 (0.56) | ADORA3NPC1IDO1 | |
| SCHEMBL3846828 | 0.67 | PTGS1 (0.58) | NPC1RAB9A | |
| SCHEMBL26708841 | 0.67 | FGFR1 (0.45) | NPC1RAB9A | |
| SCHEMBL18704564 | 0.66 | ADORA3 (0.53) | ADORA3NPC1RAB9AIDO1 | |
| SCHEMBL27883367 | 0.66 | ADORA3 (0.60) | ADORA3NPC1RAB9AIDO1 | |
| SCHEMBL11471421 | 0.65 | ADORA3 (0.55) | ADORA3NPC1RAB9AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200262827-A1 | AROMATIC DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF | BIOARDIS LLC (US) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262827-A1 | AROMATIC DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF | FGFR4, FGFR1, FGFR3 | ADORA3 2290/4885NPY5R 1264/4885NPC1 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.